A Phase 2 interventional study of CIN-102 Dose 15mg and Placebo in Idiopathic Gastroparesis, sponsored by CinDome Pharma, Inc.. Completed at 85 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by CinDome Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one is the 5th largest by enrollment of the 136 interventional ones that give a count, is one of 5 that started in 2025, is one of 38 in phase 2, and was the 171st registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 416 is above the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
CinDome Pharma, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
CinDome Pharma, Inc. has 4 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
The main questions it aims to answer are:
Participants will go through the following schedule:
Screening \& Lead-In (1-2 visits)
12-week treatment period (7 visits)
Researchers will compare the effects of the following treatments:
Key Inclusion Criteria:
Has a current diagnosis of gastroparesis defined by the following:
If receiving treatment with a Food and Drug Administration (FDA)-approved and marketed glucagon-like peptide-1 receptor agonist (GLP-1RA) for weight loss or reduce risk of major adverse cardiovascular events, and/or, receiving any other agent(s) taken for weight loss, subjects may be considered for the study if ALL of the following criteria are satisfied:
Symptoms of gastroparesis were present before starting the agent(s).
-------------------------------------------------------------------------
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 mg CIN-102, taken orally BID for 12 weeks
Drug: CIN-102 Dose 15mg
10 mg CIN-102, taken orally BID for 12 weeks
Drug: CIN-102 Dose 10mg
Placebo for CIN-102, taken orally BID for 12 weeks
Drug: Placebo
Drug pages: CIN-102 · Deudomperidone
Twice daily for 12 weeks
Twice daily for 12 weeks
Drug pages: CIN-102 · Deudomperidone
Twice daily for 12 weeks
The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score.
The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale Scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe).
Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline
The effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline
Based on the average ANMS GCSI-DD Total Score, Composite of the Nausea and Vomiting Scores, Vomiting Score, Early Satiety Score, Postprandial Fullness Score, upper Abdominal Pain Score, and Vomiting Severity Score
Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline
The percentage of subjects who are identified as responders, defined as archiving an average ≥1 point reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, and individual subscale scores
• The percentage of subjects achieving an average ≥1 point reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores
Time frame: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period
The percentage of subjects who are identified as responders, defined as archiving an average ≥0.5 point reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, and individual subscale scores
• The percentage of subjects achieving an average ≥0.5 point reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores
Time frame: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period
The percentage of subjects who are identified as responders, defined as achieving an average ≥30% reduction from baseline for each of following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores
• Occurrence of subjects achieving an average ≥ 30% reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores
Time frame: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period
The percentage of symptom-free days in the ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores.
A symptom-free day is defined as a day with severity of symptoms assessed as "none" \[ie, ANMS GCSI-DD scores of 0\])
Time frame: Over the 12-week Treatment Period
The percentage of symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores
A symptomatic week is defined as average ANMS GCSI-DD score ≥ 1
Time frame: Over the 12-week Treatment Period
The percentage of mild, moderate, severe and very severe symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores
Sponsor to provide definition of each severity score
Time frame: Over the 12-week Treatment Period
The Patient Global Impression of Change (PGIC) value
• The absolute change in PGIC over the 12-week Treatment Period
Time frame: Over the 12-week Treatment Period
The Patient Global Impression of Severity (PGIS) value
• The absolute change from baseline to Week 12 in PGIS
Time frame: From baseline to Week 12
The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score.
The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale Scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe).
Time frame: Over the final 6 weeks of the 12-week Treatment Period as compared to Baseline
The effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline
Based on the average ANMS GCSI-DD Total Score, Composite of the Nausea and Vomiting Scores, Vomiting Score, Early Satiety Score, Postprandial Fullness Score, upper Abdominal Pain Score, and vomiting severity scores
Time frame: Over the final 6 weeks of the 12-week Treatment Period as compared to Baseline
The percentage of subjects identified as responders, defined as an average ≥0.5 reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, vomiting severity scores
• Occurrence of subjects with an average ≥ 0.5 reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores
Time frame: Over the last 6 weeks of the 12-week Treatment Period
The percentage of subjects identified as responders, defined as achieving ≥30% reduction from baseline for each: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, vomiting severity scores
• Occurrence of subjects achieving a ≥ 30% reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores
Time frame: Over the final 6 weeks of the 12-week Treatment Period
The percentage of symptom-free days in the ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores
A symptom-free day is defined as a day with severity of symptoms assessed as "none" \[ie, ANMS GCSI-DD scores of 0\])
Time frame: Over the final 6 weeks of the 12-week Treatment Period
The percentage of symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores
A symptomatic week is defined as average ANMS GCSI-DD score ≥ 1
Time frame: Over the final 6 weeks of the 12-week Treatment Period
The percentage of moderate, severe and very severe symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores
Sponsor to provide definition of each severity score
Time frame: Over the final 6 weeks of the 12-week Treatment Period
The Patient Global Impression of Change (PGIC) value
• The absolute change in PGIC over the 12-week Treatment Period
Time frame: Over the final 6 weeks of the 12-week Treatment Period
The Patient Global Impression of Severity (PGIS) value
• The absolute change from baseline to Week 12 in PGIS
Time frame: Over the final 6 weeks of the 12-week Treatment Period
To assess the safety of CIN-102 compared to placebo in adult subjects with idiopathic gastroparesis from the time of informed consent until the EOS
* Incidence of clinically significant changes in laboratory parameters, physical examination findings, 12-lead ECG parameters, weight measurements, and vital signs, as assessed by the Investigator * TESAEs * TEAEs leading to premature discontinuation of study drug * Treatment-emergent clinically significant laboratory abnormalities
Time frame: Over the 12-week Treatment Period
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in May 2026, 15 months.
Of 20 phase 2 interventional studies under Gastroparesis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: CIN-102 · Deudomperidone
CinDome Pharma, Inc.